Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.

Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, Thomas J Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E Trabucco, Smruthy Sivakumar, Ethan S Sokol, Timothy R Wilson

April 2023 Genome Med

Synopsis of Social media discussions

The discussions reflect a positive response, with mentions like 'clonal context matters' and 'better responses,' indicating agreement and interest. The tone is professional and curious, emphasizing the technical aspects and clinical implications, but without fanfare reflecting a moderate overall impact.

A
Agreement
 Moderate agreement

The posts express support for the study’s findings, emphasizing that clonal PIK3CA mutations are linked to better treatment responses.

I
Interest
 High level of interest

The discussion demonstrates high curiosity, with posts highlighting the importance of mutation clonality and its predictive value.

E
Engagement
 Moderate level of engagement

Posts show moderate engagement, including recognition of the study's significance and comments on the biological implications.

I
Impact
 Moderate level of impact

The users acknowledge the study's potential to influence treatment decisions, although discussions remain focused on scientific insights rather than broad societal impact.

Social Mentions

YouTube

1 Videos

Twitter

1 Posts

Metrics

Video Views

150

Total Likes

8

Extended Reach

382

Social Features

2

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Impact of PIK3CA Mutation Clonality on Treatment Outcomes in Breast Cancer

Impact of PIK3CA Mutation Clonality on Treatment Outcomes in Breast Cancer

Mutations in the PIK3CA gene are common in ER+/HER2- breast cancer and influence sensitivity to targeted therapies. This study examines circulating tumor DNA to evaluate how multiple PIK3CA mutations impact treatment response and survival.

Medicine RTCL TV

July 29, 2023

150 views

  • Ethan Sokol
    @EthanSokol (Twitter)

    Happy to have contributed to this study showing that patients with clonal multi-PIK3CA alterations have better responses to taselisib than patients with subclonal multi-PIK3CA. Clonal context matters. https://t.co/fupr2z0Cp0 https://t.co/jnf44jfCSs
    view full post

    April 26, 2023

    6

Abstract Synopsis

  • Mutations in the PIK3CA gene, linked to the PI3K pathway, are common in HR+/HER2- breast cancer and can enhance cancer cell sensitivity to specific inhibitors.
  • Researchers examined circulating tumor DNA (ctDNA) from patients to see how multiple PIK3CA mutations (mut) could predict their response to a treatment combining fulvestrant and taselisib.
  • The findings suggest that patients with clonal multiple PIK3CAmut had fewer additional genetic alterations and showed a better response and longer survival compared to those with subclonal mutations, indicating the potential of clonal mutations as a biomarker for treatment efficacy.